

Supplementary Fig. 2. Differential prognoses of patients with ccRCC, with and without *SYNE1* mutations. Kaplan–Meier survival curves demonstrating the overall (left panel) and progression-free (right panel) survival of patients with ccRCC based on the Cancer Genome Atlas database. Hazard ratios (HR) and *p* values were calculated using a Cox proportional hazards model and the log-rank test, respectively. The number of at-risk patients (no. at risk) was recorded every 50 months up to 150 months.

